Article Text

Download PDFPDF
EV220/#529  Outcomes of patients treated with hyperthermic intraperitoneal chemotherapy and cytoreductive surgery compared to surgery alone in epithelial ovarian cancer: a systematic review and meta-analysis
  1. Myriam Jerbaka1,
  2. Nadine El Kassis1,
  3. Rim Abou Chakra1,
  4. Christopher El Hadi2,
  5. Racha Aaraj3,
  6. Wissam Arab1,
  7. Elias Saleme1,
  8. Iman Feghaly1,
  9. Karen Ghoul3,
  10. Hussein El Hajj4,
  11. Donal Brennan5 and
  12. David Atallah1,6
  1. 1Université Saint-Joseph, Obstetrics and Gynecology, Beirut, Lebanon
  2. 2Lebanese American University, Internal Medicine, Beirut, Lebanon
  3. 3Université Saint-Joseph, Beirut, Lebanon
  4. 4Université Paris Descartes, Paris, France
  5. 5University College Dublin Gynaecological Oncology Group, Ucd School of Medicine, Mater Hospital, Dublin, Ireland
  6. 6Hôtel-Dieu de France University Hospital, Obstetrics and Gynecology, Beirut, Lebanon

Abstract

Introduction Epithelial ovarian cancer (EOC) is challenging in terms of diagnosis and treatment. Although HIPEC showed an increase in overall survival (OS) and event-free survival (EFS), its application remains unguided. This meta-analysis compares patients with advanced primary and recurrent EOC undergoing cytoreductive surgery (CRS) and HIPEC versus CRS alone and is registered in PROSPERO with the number CRD42018102289 with registry name of Professor David Atallah.

Methods We searched clinicaltrials.gov, Embase, Cochrane, PubMed, Scopus, Google scholar, Web of science and Grey literature without restriction on time for an extensive analysis, investigating OS, EFS and complications, in HIPEC and CRS versus CRS-alone, following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) reporting guidelines

Results We included 2251 patients from 18 studies evaluating OS. Among these, 13 studies assessed EFS. HIPEC significantly improved OS (HR = 0.65, 95% CI: 0.5 to 0.85) and EFS (HR = 0.71, 95% CI: 0.58 to 0.87). Specifically, patients with primary EOC undergoing interval debulking surgery (IDS) with HIPEC, had upswing of OS and EFS. The open technique exhibited optimum outcomes. Studies including paclitaxel-only regimens achieved amelioration, while combination with doxorubicin had worse outcomes. The incidence of grade III-IV complications is higher in HIPEC groups, compared to CRS-only groups with a pooled RR 1.229 (95% Cl: 1.057-1.43).

Conclusion/Implications The incorporation of HIPEC in IDS improved OS and EFS in primary EOC while the incidence of complications are higher in HIPEC groups compared to CRS groups. Therefore, the efficacy of HIPEC during CRS in the management of EOC should be further investigated.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.